Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2020. The report serves as a transaction notification regarding a specific executive compensation event rather than a comprehensive financial results announcement.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data disclosed relates to a specific executive transaction:
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award Plan.
- Executive: Mr. L. Miels, President, Global Pharmaceuticals.
- Instrument: 25,999.998 notional Ordinary Shares (ISIN: GB0009252882).
- Price per Share: £14.352.
- Total Cash Payment: £373,151.97 (subject to applicable tax withholding).
- Transaction Date: September 4, 2020.
Material Changes
The filing does not report material changes to the company's financial position, operations, or market conditions compared to prior periods. It solely documents the vesting of 25% of an award originally granted on February 14, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a regulatory disclosure of a Person Discharging Managerial Responsibilities (PDMR) transaction.
Investor Verification Points
- Verify the vesting schedule and performance conditions of the GlaxoSmithKline Deferred Investment Award Plan.
- Confirm the tax withholding implications for the executive cash payment of £373,151.97.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or other earnings releases for broader financial metrics.